The Lynx Group

2018 ASCO Insights

What the Next Generation of Cancer Biomarkers May Involve

Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

How MSI and TMB Factor into Current Biomarker Testing Panels

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Best Practices in How Oncologists and Pathologists Can Work Together to Optimize Biomarker Testing for their Patients with Cancer

Dr Sanjiv Agarwala describes best practices developed at St. Luke’s Cancer Center, where a committee has been formed in which clinicians and pathologists meet to reach consensus on reflex testing of molecular biomarkers, as well as the value of biomarker testing in enhancing patient care.

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Biomarker Data in Melanoma Presented at ASCO 2018 Are Largely Extensions of Previous Studies Rather Than New Discoveries

Dr Sanjiv Agarwala argues that much of the biomarker data in melanoma presented at ASCO 2018 are around the value of PD-L1 testing; however, even PD-L1–negative melanoma patients seem to respond to anti–PD-1 therapy, although some studies suggest PD-L1–negative patients may be better candidates for combination immunotherapy.

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

How Real-World Data Are Consolidating Our Knowledge Regarding Melanoma Treatment

Dr Sanjiv Agarwala reviews real-world data presented at ASCO 2018 on immunotherapy of melanoma that serve to reassure providers regarding current treatment approaches, but do not offer any significant practice-changing results.

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights and Video Library

New Clinical Trial Data in Advanced Melanoma Presented at ASCO 2018: How Will it Change How You Practice?

Dr Sanjiv Agarwala talks about exciting new results presented at ASCO 2018 in melanoma, including the durability of anti–PD-1 therapy in providing 40% overall survival at 5 years, updates on adjuvant therapy showing superiority of anti–PD-1 over anti–CTLA-4, and new results in combining immunotherapies.

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights and Video Library

The Greatest Challenges in Incorporating Biomarkers into Cancer Care

Dr David Spigel discusses challenges and solutions to incorporating cancer biomarkers into patient care, including finding pathology resources to do the testing, issues around reimbursement, and educating colleagues on the value and operational aspects of biomarker testing in delivering personalized therapy to patients with cancer.

David Spigel, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

The Best Molecular Biomarkers Available for Informing Immunotherapy of Cancer

Dr David Spigel talks about currently available and emerging biomarkers that predict the greatest sensitivity to immunotherapy, including his insight into PD-L1, MSI, and TMB.

David Spigel, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

How Oncologists and Pathologists Can Best Collaborate to Provide Precision Medicine for Their Patients

Dr David Spigel discusses how medical oncologists and the rest of the cancer care team can best communicate with pathologists to help make informed treatment decisions for individual patients and set up new assays for emerging biomarkers as they are discovered.

David Spigel, MD

Video Categories: 2018 ASCO Insights and Video Library

The Most Important Advances in Precision Medicine Being Presented at ASCO 2018

Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required [ Read More ]

David Spigel, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Sign me up!